Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR alpha/beta Depleted DLI in Hematologic Malignancies
NCT05350163Phase 1Terminated
- Start
- Apr 2022
- Primary completion
- Sep 2023
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of t-cell receptor alpha/beta depleted donor lymphocyte infusion in acute lymphoblastic leukemia (ALL), Myeloid malignancy and plasma cell neoplasm (6 cohorts). Primary endpoint: Treatment-emergent Serious Adverse Events. Started Apr 2022; status: terminated.
02
Drugs
t-cell receptor alpha/beta depleted donor lymphocyte infusion
03
Conditions
acute lymphoblastic leukemia (ALL)Myeloid malignancyplasma cell neoplasm
Beyond the preview
Go deeper on NCT05350163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05350163.